Expert Interview
What Will Phase 3 Results for EVK-001 in Acute and Recurrent Diabetic Gastroparesis in Women Mean for Evoke?
Ticker(s): EVOKA gastroenterologist with experience treating diabetic gastroparesis in women and a familiarity with EVK-001.
What is your background treating diabetic gastroparesis? How commonly do you see the disease? Are you seeing numbers of these patients increase over time as diabetes becomes more prevalent?
Added By: kcmckeeWhat is currently your preferred method of treating gastroparesis? Are there any others widely used? Does this differ for men and women? Does it make sense to you that EVOK's drug is just being tested on women?
Added By: kcmckeeWhat are your thoughts on the EVOK data thus far? Are there any promising or concerning signs in the data that might help reveal if it will be approved?
Added By: kcmckeeWhat sort of factors are most important to you in prescribing a drug? Based on the Phase 1 and 2 data, do you think EVK-101 could meet your criteria?
Added By: kcmckeeHow common is diabetic gastroparesis relative to any other type of the disease? Are other segments within the disease growing? Do you think EVK-001 could be used in other manifestations of the disease down the road?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
